v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Feb. 23, 2022
Dec. 31, 2024
Dec. 31, 2023
Jun. 28, 2023
Cash equivalents   $ 0 $ 0  
Deferred underwriting fee payable       $ 10,812,500
Federal deposit Insurance corporation coverage limit   250,000    
Unrecognized tax benefits   $ 0 $ 0  
Purchase price, per unit   $ 11.43    
Anti-dilutive securities attributable to warrants   24,138,333 24,138,333  
Additional paid in capital   $ 8,802,978 $ 10,964,930  
Aspire Biopharma Inc [Member]        
Common stock par value   $ 0.00005 $ 0.00005  
Post split par value     $ 0.00005  
Additional paid in capital   $ 1,215,113 $ 957,500  
Shares issued     150,000  
Aspire Biopharma Inc [Member] | Trademarks [Member]        
Amortization of long lived assets   $ 4,844,982    
Previously Reported [Member] | Aspire Biopharma Inc [Member]        
Common stock par value   $ 0.01    
Additional paid in capital     $ 758,000  
Revision of Prior Period, Adjustment [Member] | Aspire Biopharma Inc [Member]        
Common stock par value     $ 0.001  
Additional paid in capital     $ 957,500  
Effect of Restatement [Member] | Aspire Biopharma Inc [Member]        
Additional paid in capital     $ 199,500  
Warrant [Member]        
Purchase of aggregate shares 24,138,333      
Purchase price, per unit $ 11.50      
Common Class A Subject to Redemption [Member]        
Ordinary shares subject to possible redemption   577,644 1,803,729  
IPO [Member]        
Offering costs   $ 16,418,580    
Underwriting fees   5,000,000    
Deferred underwriting fee payable   10,812,500    
Other costs   $ 606,080    
Purchase price, per unit $ 10.25